CAIRO - 28 May 2025: The Holding Company for Pharmaceuticals, Chemicals, and Medical Supplies has launched a strategic joint venture with American pharmaceutical firm Dawah Pharma.
This partnership marks a significant step in Egypt’s push to expand its pharmaceutical footprint globally, with plans to manufacture and export a broad range of pharmaceutical products and dietary supplements to international markets.
Minister of Public Business Sector Mohamed Shimi announced that the new venture will produce a diverse portfolio of products, including ampoules, sterile injections, ophthalmic solutions, over-the-counter (OTC) medications, and dietary supplements.
The joint venture structure grants the Egyptian side a 40 percent share, while Dawah Pharma holds a 60% majority stake. The newly formed company will focus primarily on exporting its products and opening new channels in global markets.
In a milestone move, the partnership’s first phase will see the manufacture and export of six specific dietary supplements to the United States—marking the first time in the Holding Company’s history to achieve such a feat after meeting rigorous international standards and requirements.
The agreement also leverages advanced pharmaceutical manufacturing technologies, including the production of syrups, tablets, ampoules, pre-filled syringes, and transdermal patches.
These innovations are expected to significantly accelerate product deployment and support long-term growth for the Holding Company and its subsidiaries.
Shimi stressed that the new company will strictly follow international regulatory standards, particularly those enforced by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Adhering to these benchmarks will boost the global competitiveness of Egyptian pharmaceuticals—not only in the high-demand markets of Europe and North America but also in emerging markets across Africa and Asia.
Wed, May. 28, 2025
